Clinical Trial Update: Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating the safety and efficacy of a CD19-BCMA targeted CAR-T therapy for refractory generalized myasthenia gravis. The study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• CD19-BCMA targeted CAR-T therapy (CD19-BCMA CAR-T)

Snippet

Sponsor: Ting Chang, MD | Conditions: Myasthenia Gravis | Phase 1 | Status: RECRUITING